These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25336034)

  • 1. Recent advances in the treatment of hepatitis C.
    Dhingra A; Kapoor S; Alqahtani SA
    Discov Med; 2014 Oct; 18(99):203-8. PubMed ID: 25336034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rapid evolution of treatment strategies for hepatitis C.
    Muir AJ
    Am J Gastroenterol; 2014 May; 109(5):628-35; quiz 636. PubMed ID: 24732866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV direct-acting antiviral agents: the best interferon-free combinations.
    Schinazi R; Halfon P; Marcellin P; Asselah T
    Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral treatment of hepatitis C.
    Feeney ER; Chung RT
    BMJ; 2014 Jul; 348():g3308. PubMed ID: 25002352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir (Sovaldi) for the treatment of hepatitis C.
    Lam B; Henry L; Younossi Z
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):555-66. PubMed ID: 24918162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.
    Summers BB; Beavers JW; Klibanov OM
    J Pharm Pharmacol; 2014 Dec; 66(12):1653-66. PubMed ID: 25175944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir for the treatment of hepatitis C virus.
    Asselah T
    Expert Opin Pharmacother; 2014 Jan; 15(1):121-30. PubMed ID: 24289735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
    Asselah T; Marcellin P
    Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.
    Puoti M; Panzeri C; Rossotti R; Baiguera C
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S206-11. PubMed ID: 25458781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
    Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
    J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C treatment: an incipient therapeutic revolution.
    deLemos AS; Chung RT
    Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
    Hill A; Khoo S; Fortunak J; Simmons B; Ford N
    Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of HCV patients with cirrhosis with direct acting antivirals.
    Boccaccio V; Bruno S
    Liver Int; 2014 Feb; 34 Suppl 1():38-45. PubMed ID: 24373077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
    Kim B; Trivedi A; Thung SN; Grewal P
    Semin Liver Dis; 2014 Feb; 34(1):108-12. PubMed ID: 24782264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.